At which stage of chronic kidney disease should dyslipidemia be treated?

Nature Clinical Practice Nephrology

Volumn 2, Issue 4, 2006, Pages 176-177

  Krane, Vera ^a   Wanner, Christoph ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; GRAFT RECIPIENT; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEMODIALYSIS; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; MALNUTRITION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; SHORT SURVEY; STROKE; TRIACYLGLYCEROL BLOOD LEVEL;

CARDIOVASCULAR DISEASES; CHRONIC DISEASE; COMORBIDITY; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; RENAL DIALYSIS;

EID: 33646864315     PISSN: 17458323     EISSN: 17458331     Source Type: Journal    
DOI: 10.1038/ncpneph0129     Document Type: Short Survey

References (10)

1. Tonelli M et al. (2004) Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110: 1557-1563
2. Sever PS et al. (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361: 1149-1158
3. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 7-22
4. Go AS et al. (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305
5. Fried LF et al. (2001) Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 59: 260-269
6. Athyros VG et al. (2004) The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease: a subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 57: 728-734
7. Wanner C et al. (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238-248
8. Liu Y et al. (2004) Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 291: 451-459
9. Holdaas H et al. (2003) Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 361: 2024-2031
10. Holdaas H et al. (2005) Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation. Nephrol Dial Transplant 20: 974-980